Research Topic · Peer-Reviewed

Proteasome Inhibitors

Proteasomes are essential cellular structures responsible for breaking down and recycling unwanted and damaged proteins in cells. Proteasome inhibitors are a class of drugs that inhibit the function of the proteasome and thereby cause the accumulation of harmful proteins in cells leading to apoptosis or cell death. …

Curated from this journal's research 📚 2 peer-reviewed articles cited Cited 18× across the literature 🔖 ISSN 2328-0182 🗓 Reviewed June 2026

Overview

Proteasomes are essential cellular structures responsible for breaking down and recycling unwanted and damaged proteins in cells. Proteasome inhibitors are a class of drugs that inhibit the function of the proteasome and thereby cause the accumulation of harmful proteins in cells leading to apoptosis or cell death. This mechanism of action is highly relevant in the field of pharmaceutical science and technology, and the use of proteasome inhibitors has shown promising results in the treatment of various types of cancer. There are two main types of proteasome inhibitors: bortezomib and carfilzomib. Bortezomib was the first proteasome inhibitor to be approved by the FDA in 2003 for the treatment of multiple myeloma, a type of blood cancer. Carfilzomib, approved in 2012, is a more potent proteasome inhibitor and has shown significant clinical benefit in relapsed or refractory multiple myeloma patients. Proteasome inhibitors also have potential applications in the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis and psoriasis. The proteasome plays a critical role in regulating inflammation, and the inhibition of proteasome activity has been shown to reduce inflammation and disease severity in animal models of these conditions. In summary, proteasome inhibitors represent an exciting area of pharmaceutical science and technology with promising applications in cancer and autoinflammatory disease. With further research and development, proteasome inhibitors have the potential to revolutionize the treatment of these diseases and improve patient outcomes.

Research published in this journal

2 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 2 articles above have been cited 18 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Proteasome Inhibitors, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Advanced Pharmaceutical Science And Technology (ISSN 2328-0182).

Journal editorial board
natalia malara · Italy Saba Khalilpour · Italy Haseeb Khan · United States

This page summarises published research for orientation; it is not medical or professional advice.